Boudes Pol F 4
4 · GALECTIN THERAPEUTICS INC · Filed Mar 29, 2021
Insider Transaction Report
Form 4
Boudes Pol F
Chief Medical Officer
Transactions
- Award
Stock option (right to buy)
2021-03-25+50,000→ 50,000 totalExercise: $2.11Exp: 2031-03-25→ Common Stock (50,000 underlying) - Award
Stock option (right to buy)
2021-03-25+100,000→ 100,000 totalExercise: $2.11Exp: 2031-03-25→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]Such options vest as follows: 25% on each on September 30, 2021, March 31, 2022, September 30, 2022 and March 31, 2023.
- [F3]Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results.